Although Kelly et al. (1) demonstrate the effectiveness of the outer-membrane-vesicle, strain-specific, meningococcal vaccine known as “MeNZB” in the overall New Zealand population with reported vaccine effectiveness of 73 percent (95 percent confidence interval: 52, 85), this may not reflect the true picture.

First, there is an indication of the poor fit of the model (1, figure 1), where the model’s rates of disease determined by modes in children less than 1 year of age are considerably less than those in children 1–4 years of age. Data published elsewhere show the highest rates to be in children less than 1 year of age (2).

Further, there appear to have been difficulties with the model that may influence the vaccine effectiveness estimate. The model assumes that vaccine uptake within an analysis stratum was random for an individual’s risk of disease. Despite great effort to achieve high coverage, this assumption may not be true. Ethnicity and household crowding (3) are known to be major risk factors for disease. Coverage is known to have varied by ethnicity (www.moh.govt.nz). Indigenous Maori who sustained a higher rate of disease prior to vaccine introduction had 67 percent vaccine coverage among those aged from 6 weeks to 4 years compared with the remaining population with 74 percent coverage. Ethnicity was included in the model, but household crowding and other factors were not. An indication that coverage may have been reduced in subgroups with risk factors not included in the model may be seen in the crude estimates of vaccine effectiveness (the risk ratios of the rates of disease in the unvaccinated vs. the vaccinated cases). These crude 2005 risk ratios (1) do not reflect decreasing geometric mean antibody titers (GMTs) with decreasing age (4, 5). Antibody levels by age are likely to be reflected in vaccine efficacy levels (6–8). Kelly et al. (1) observed a crude risk ratio four times higher in the children aged 1–4 years compared with those aged 5–19 years, contrary to that expected. Older children were vaccinated in school with high coverage nationwide. Vaccination of preschool children was general over the 6 years of the study and the corresponding change in the proportion of cases included in the analysis (2).

Kelly et al. (1) raise the question of long-term vaccine effectiveness. The group C meningococcal vaccine used in the United Kingdom was a conjugate vaccine producing very high GMTs (e.g., 629 after a three-dose priming series in one trial in infants) (9). In contrast, in New Zealand infants aged 6–8 months after three doses of MeNZB vaccine, an outer-membrane-vesicle vaccine, lower GMTs of 27 were observed (4). Higher titers are likely to remain longer. In persistence studies, antibody decay occurred very rapidly (GMT of 2 at 7 months after the third dose) (5).

Although it seems likely that the mass vaccine program has indeed had some effect, the concerns raised above shed some doubt on the reliability of the estimates as quoted.

ACKNOWLEDGMENTS

Conflict of interest: D. L. and J. S. were part of the MeNZB trials team sponsored by the New Zealand Ministry of Health; S. C. with J. S. and D. L. provided expert advice to the New Zealand Ministry of Health for the strategy to control New Zealand’s meningococcal epidemic.

REFERENCES


Diana Lennon¹, Joanna Stewart², and Sue Crengle³
(e-mail: d.lennon@auckland.ac.nz)

¹ Department of Community Paediatrics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
² Department of Biomedical Statistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
³ Department of Maori and Pacific Health, School of Medical Sciences, The University of Auckland, Auckland 1142, New Zealand

DOI: 10.1093/aje/kwn051; Advance Access publication